Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company Drug

Zhifei Biological Gains Bangladesh Approval for Dysentery Vaccine Trial

Fineline Cube Apr 9, 2025

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has received clearance from the Directorate General...

Company Drug

Hengrui Pharmaceuticals’ Vunakizumab Approved for Ankylosing Spondylitis

Fineline Cube Apr 9, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Drug

CSPC Pharmaceutical’s JMT108 Gains FDA Approval for Advanced Malignant Tumor Trials

Fineline Cube Apr 9, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...

Company Drug

Amgen’s Uplizna Approved by FDA for IgG4-Related Disease

Fineline Cube Apr 8, 2025

US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the...

Company Drug

J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment

Fineline Cube Apr 8, 2025

The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...

Company Deals

TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China

Fineline Cube Apr 8, 2025

China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...

Company Drug

J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma

Fineline Cube Apr 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...

Policy / Regulatory

Shenzhen Unveils Comprehensive Policy Package to Boost Biopharma Innovation

Fineline Cube Apr 8, 2025

Shenzhen has launched an ambitious policy package, “Several Measures to Support Pharmaceuticals and Medical Devices...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Accepted for Review by NMPA

Fineline Cube Apr 8, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free...

Company Drug

SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study

Fineline Cube Apr 8, 2025

Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...

Company Drug

Luye Pharma’s Toludesvenlafaxine Approved for Marketing in Macau

Fineline Cube Apr 8, 2025

China-based Luye Pharma Group (HKG: 2186) announced that its extended-release depression treatment, toludesvenlafaxine (LY03005), has...

Company Drug

Shanxi Yanghe Medical Technology Faces Production Halt Over GMP Violation

Fineline Cube Apr 8, 2025

China’s National Drug Alliance Procurement Office has imposed manufacturing suspensions on Shanxi Yanghe Pharmaceutical Technology’s...

Company Drug

Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion

Fineline Cube Apr 8, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...

Company Drug

Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors

Fineline Cube Apr 8, 2025

China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...

Policy / Regulatory

Beijing Unveils Measures to Accelerate Innovative Drug Development and Regulatory Efficiency

Fineline Cube Apr 8, 2025

The Beijing Municipal Medical Insurance Bureau, in collaboration with seven other bureaus, has released the...

Company Deals

Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China

Fineline Cube Apr 8, 2025

In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...

Company Deals

Siemens Set to Acquire Dotmatics for $5.1 Billion to Boost Life Sciences R&D

Fineline Cube Apr 8, 2025

German industrial giant Siemens AG (ETR: SIE) has announced plans to acquire US-based Dotmatics, a...

Company Deals

Lynmou Medical Secures Series A Funding for Endoscope Expansion

Fineline Cube Apr 8, 2025

Lynmou Medical, a Hangzhou-based provider of soft endoscope solutions, has reportedly secured “tens of millions”...

Company Drug

Phanes Therapeutics Gains CDE Approval for Peluntamig Phase II Trial in SCLC and NEC

Fineline Cube Apr 8, 2025

Sino-US biotech Phanes Therapeutics Inc. announced receiving approval from the Center for Drug Evaluation (CDE)...

Company Deals

Hengrui Pharmaceuticals Licenses SHR7280 to Merck for Assisted Reproduction

Fineline Cube Apr 8, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has entered into a licensing agreement with...

Posts pagination

1 … 203 204 205 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.